Third, unlike wild-type EGFR patients, EGFR mutations affect anti-tumor immune responses by modulating factors that may be associated with tumor microenvironmental status (for instance, tumor-infiltrating lymphocytes, regulatory T cells, and exosome CD73) (76–78). The gene discussed is EGFR; the disease is neoplasm.